Ocugen Q2 results: dosing in Phase 2/3 trial, $11mln Korean rights deal.

• Ocugen initiated dosing in OCU410ST Phase 2/3 GARDian3 clinical trial. • Actively dosing patients in OCU400 Phase 3 liMeliGhT clinical trial. • On track for 2026 BLA filing. • Signed binding term sheet for exclusive Korean rights to OCU400. • Totaling up to $11 million in upfront fees and near-term development milestone payments. • OrthoCellix reverse merger intended to unlock NeoCart and regenerative cell therapies value.

Ocugen, Inc. (NASDAQ: OCGN), a leading biotechnology company focused on gene therapies for blindness diseases, has reported significant progress in its Q2 2025 financial results and business update. The company has initiated dosing in the OCU410ST Phase 2/3 GARDian3 clinical trial for Stargardt disease and continues actively dosing patients in the OCU400 Phase 3 liMeliGhT trial for retinitis pigmentosa, aiming for a Biologics License Application (BLA) filing in 2026 [1].

Ocugen has also signed a binding term sheet for exclusive Korean rights to OCU400, with potential upfront fees and milestone payments totaling up to $11 million. Additionally, the company announced a strategic reverse merger with OrthoCellix and Carisma Therapeutics, aiming to unlock value from NeoCart technology for regenerative cell therapies [1].

The company reported $27.3 million in cash as of June 30, 2025, providing a runway into Q1 2026, with a quarterly net loss of $0.05 per share. The OCU410ST Phase 2/3 GARDian3 trial demonstrated promising Phase 1 results, showing 23% slower geographic atrophy lesion growth and a 2-line gain in visual acuity [1].

Ocugen's financial results and recent business highlights will be discussed during a conference call and webcast scheduled for 8:30 a.m. ET today. The call will be open to all listeners and will include a question-and-answer session following the prepared remarks [1].

References:
[1] https://www.stocktitan.net/news/OCGN/ocugen-provides-business-update-with-second-quarter-2025-financial-yvcdaxk8aj25.html